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ABSTRACT
RNA editing regulates mitochondrial gene expres-
sion in trypanosomatid pathogens by creating func-
tional mRNAs. It is catalyzed by a multi-protein
complex (the editosome), and is found to be essen-
tial in both insect stage and mammalian blood
stream form of Trypanosoma brucei. This particular
form of RNA editing is unique to trypanosomatids,
and thus provides a suitable drug target in
trypanosomatid pathogens. Here, we demonstrate
the feasibility of a rapid and sensitive
fluorescence-based reporter assay to monitor RNA
editing based on ribozyme activity. We could
validate our new assay using previously identified
inhibitors against the essential RNA editing ligase.
The principle advantages of this assay are: (i) the
use of non-radioactively labeled materials, (ii) sensi-
tivity afforded by fluorescence instrumentation ap-
plicable to high-throughput screening of chemical
inhibitors against the essential editosome and (iii)
a rapid and convenient ‘mix and measure’ type of
assay in low volume with a high signal to noise
ratio. This assay should enhance rapid identification
and characterization of the editosome inhibitors
primarily based on the overall composition of
the editosomes from T. brucei. These inhibitors
could also be tested against the editosomes from
the closely related pathogens including T. cruzi
and Leishmania species.
INTRODUCTION
The three major trypanosomatid pathogens; Trypanosoma
brucei, T. cruzi, and Leishmania major are responsible for
devastating human diseases around the world. They are
the causative agents of African sleeping sickness, Chagas
disease, and Leishmaniasis, respectively (1,2). Current
trypanocidal drugs are found to be generally unsuitable
for treatment as they are often toxic, not very eﬀective and
can lead to drug resistance (3–6). Therefore, creating a
new, eﬀective, and safe drug is essential for the treatment
of diseases caused by trypanosomatids. There are several
molecular processes that are unique to trypanosomatids.
One such process is RNA editing, which regulates parasite
gene expression by creating mature functional mRNAs
for multiple components of the mitochondrial oxidative
phosphorylation system. RNA editing is catalyzed by a
large multi-protein complex known as editosome and is
a form of post-transcriptional RNA processing by which
uridylates (Us) are inserted and deleted in mitochondrial
mRNAs as speciﬁed by small guide RNAs (gRNAs; 7–9).
Four major enzymatic activities are required for inser-
tion and deletion of Us; (i) endonucleolytic cleavage of
pre-edited mRNA at the editing site, (ii) U insertion by
terminal uridylate trasferase (TUTase) or (iii) U deletion
by Uridylate-speciﬁc 30 exoribonuclease (30-ExoUase), and
(iv) ligation of RNA fragments of the edited products by
RNA ligases (10). Puriﬁcation protocols developed using
monoclonal antibodies speciﬁc for editosome proteins in
combination with column chromatography or a TAP tag;
identiﬁed 21 proteins in the core complex (11). Knockout
or knockdown of some of the editosome proteins results in
loss of editosome function and, consequently, in parasite
death (12–22), suggesting editing as an essential process
and a suitable target for drug development. However, the
exact roles of the editosome proteins in RNA editing and
the dynamic processing and assembly of the editosome,
which might involve interactions among multi-protein
complexes and changes in their composition, remain to
be determined. Inhibition of diﬀerent steps of the editing
process and subsequent assays on the resultant aberrant
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dynamics should allow resolving some of these remaining
questions. To achieve this, a repertoire of inhibitors
against diﬀerent editosome proteins could be very useful.
This repertoire will not only give us useful hints about the
individual roles of editosome proteins and molecular
dynamics of editosome assembly, but also provide us
with potential drugs against trypanosomatid pathogens.
In order to ﬁnd such inhibitors we need to develop an
assay(s) that can rapidly and accurately monitor the
RNA editing process.
Three diﬀerent biochemical assays have been developed
and used to monitor RNA editing activities: (i) full-round
in vitro RNA editing assay (23), (ii) pre-cleaved RNA
editing assay (24,25) and (iii) a hammerhead ribozyme
(HHR)-based assay (26). The ﬁrst two assays rely on
direct visualization of RNA editing product, while the
latter uses a HHR and its substrate as a reporter for
RNA editing eﬃciency. One major drawback of the
full-round editing assay is its low detection limit (3–5%),
while pre-cleaved RNA editing assay bypasses the initial
rate limiting step of endonucleolytic cleavage and is useful
for examining the U insertion/deletion and RNA ligation
catalytic steps of RNA editing. To overcome the low de-
tection limit of full-round editing assay, an in vitro RNA
editing assay based on the creation of a HHR was de-
veloped (26). This assay entails the conversion of an
inactive ribozyme to an active ribozyme, which is specif-
ically edited by the editosome via accurate in vitro deletion
editing in which three Us are removed as directed by the
appropriate gRNA. The edited functional ribozyme is
then used to cleave its targeted RNA substrate. This
HHR-mediated assay increased the RNA editing detection
limit up to 16.8% (26) .
The above mentioned assays suﬀer from limitations and
drawbacks such as low sensitivity, use of radiolabeled ma-
terials and most importantly inapplicability for high-
throughput screening.
In this study, we have developed a ‘mix and measure’
HHR-based in vitro reporter assay to monitor RNA
editing for rapid identiﬁcation of the editosome inhibitors.
Our assay utilizes a ﬂuorescent resonance energy transfer
(FRET) substrate that can monitor full-round deletion
RNA editing. We show that this new assay has higher
sensitivity compared to previously reported full-round
deletion RNA editing assays with a high signal to noise
ratio, avoids the use of radiolabel material, and is applic-
able for high-throughput screening of chemical libraries
against the essential editosome proteins. We have also
used our assay to conﬁrm the ﬁndings of Amaro et al.
(27) who have recently reported inhibitors against
kinetoplastid RNA editing ligase 1 (KREL1) using a com-
bination of in silico analysis and in vitro adenylation assay.
Using our assay, we have shown that the best KREL1
inhibitor reported by Amaro et al. (27) is also capable of
inhibiting the full-round deletion RNA editing in the
presence of puriﬁed editosome, suggesting it as a
suitable candidate for development of novel trypanocidal
drugs.
MATERIALS AND METHODS
Preparation of RNAs
The pre-edited ribozyme (pre-A6Rbz) for deletion assay,
the active ribozyme (A6Rbz), the guide RNA (gA6Rbz)
and the guide competitor (gA6Rbz-comp) were trans-
cribed in vitro by T7 polymerase RiboMAX transcription
kit (Promega) from synthetic DNA oligonucleotides
(pre-A6RBz: 50-ACATTTGATCTATTGTTTCGTCCTC
ACGGACTCATCAAAAAGTCACAACTTTCCCTTT
CTCTCCTCCCCCTAACCTTTCCCCCTATAGTGAG
TCGTATTA-30; A6Rbz: 50-ACATTTGATCTATTGTTT
CGTCCTCACGGACTCATCAGTCACAACTTTCCCT
TTCTCTCCTCCCCCTAACCTTTCCCCCTATAGTG
AGTCGTATTA-30; gA6Rbz: 50-AAAAAAAAAAAAA
AAAATAATTATCATATCACTGTCAAGGGAAAGT
TGTGAGGGTGATGAGTCCGTGTATATCCCCCTA
TAGTGAGTCGTATTA-30; gA6Rbz-comp: 50-GGATA
TACACGGACTCATCACCCTCACAACTTTCCCTTG
ACAGTGATATGATAATTATTTTTTTTTTTTTTT
TTCCCTATAGTGAGTCGTATTA-30) in combination
with a T7 oligonucleotide, where the sequence comple-
mentary to the T7 promoter sequence is underlined. All
RNAs were puriﬁed by electrophoresis through 9%
sequencing gels as previously described (28). Unlabeled
HHR substrate (50-GAUCUAUUGUCUCACA-30) was
synthesized by Integrated DNA Technologies (IDT)
and the ﬂuorescent labeled substrate, 50-FAM (6-carbo-
xyﬂuorescein) –GAUCUAUUGUCUCACA-TAMRA
(6-carboxytetramethylrhodamine)  30 was synthesized
and HPLC puriﬁed by Eurogentec. Radiolabeling of
RNA at the 30-terminus was performed by [50-
32P]pCp
ligation (29). The partial T1 RNA sequencing was per-
formed using the Ambion sequencing kit.
Preparation of mitochondrial extract (editosome)
and western blot analyses
Mitochondrial extract from procyclic form of T. brucei
1.7A wild-type cell lines (30) was prepared from 11 10
9
cells (400ml of 2.7 10
7 cells/ml) by centrifugation in a
linear 10–30% (vol/vol) glycerol gradient and fractionated
into 21 fractions (500ml each) as described before
(16,31,32,33). From each fraction, 15ml was separated
on 10% SDS–PAGE, blotted onto the PVDF
membrane, and probed with four monoclonal antibodies
(MAbs) against KREPA1 (1:25 dilution), KREPA2 (1:50
dilution), KREL1 (1:50 dilution) and KREPA3 (1:25
dilution) (34). Goat anti-mouse IgG HRP conjugate
(Bio-Rad) was used as the secondary antibody at 1:5000
dilutions in PBST buﬀer. The western blot was developed
by ECL Kit (Amersham).
Editosome complex was also puriﬁed by tandem aﬃnity
puriﬁcation from 2l of TbREL1-TAP expressing T. brucei
cells as previously described (31). From each puriﬁcation
method, the fractions were tested for deletion editing
activity, and the fractions with the highest activity were
used for the experiments. Puriﬁed fractions were stored
in 15% (vol/vol) glycerol at  80 C between puriﬁcations
and use in editing assays. The mitochondrial extract and
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determined using Bradford assay (BioRad).
Full-round in vitro RNA editing reactions
Assays for RNA editing reactions were performed essen-
tially as described before (26) with some modiﬁcations.
For radiolabeled full-round deletion RNA editing
assays, [
32p] pCp-pre-A6Rbz (1pmol) was initially
annealed to gA6Rbz (2.5pmol) at 70 C and then cooled
down at room temperature for 15min. In the next step, the
annealed preA6Rbz and gA6Rbz were added to the
editing reaction buﬀer containing 1  HHE [25mM
HEPES pH 7.9, 10mMMg (OAc)2, 50mM KCL and
1mM EDTA], 1mM ATP, 5mM CaCl2 and 83ng/ml
of Toroula RNA, and 5ml of editosome puriﬁed from
mitochondrial preparation was added. Then, RNA
editing reactions were incubated at 28 C. The reactions
were stopped after 4h by adding a stop buﬀer containing
2.5% SDS and 130mM EDTA. RNA was then extracted
by phenol:chloroform:isoamyl alcohol and run on 9%
polyacrylamide gel containing 7M urea for 6–8h at
55W. Finally, results were visualized by PhosphorImager.
For HHR-based assay, we followed the same protocol
as the full-round RNA editing assay except that
pre-A6Rbz was not radiolabeled and after 4h incubation
at 28 C, 25pmol of guide competitor (gA6Comp) was
added (10  more than gA6Rbz) and reaction was
heated at 95 C for 10min and cooled down at room tem-
perature for at least 10min. Then, 2pmol of [
32p] pCp
HHR substrate was incubated with editing reaction
buﬀer at 37 C for 45min. The cleavage product
were detected on a 15% polyacrylamide gel using
PhosphorImager.
Fluorescent-based RNA editing assays
In this assay, instead of [
32p] pCp HHR substrate, 15pmol
of ﬂuorescent-labeled substrate was added to the editing
reaction described above. The samples were then
transferred to Rotor Gene 3000, where they were
incubated for  2h at 37 C. Real-time measurements of
the ribozyme activity were recorded at intervals of 1min.
The emission spectra of FAM and TAMRA were 535nm
and 582nm, respectively, and the excitation wavelength
was 470nm for FAM. The rate of increase of the signal
from FAM was used to measure the activity and, thus, the
concentration of the edited ribozyme. In order to deﬁne
the quality of our assay, the Z-factor (35) was calculated
for 20 repetitions as:
Z ¼ 1 
3  p þ  n

 p    n
   
In which ( ) is the SD of the acquired signal, ( ) is its
average, (p) indicates the positive control and (n) indicates
the negative control.
KREL1 inhibitors (NCI; 45207 and 16209; 27) were
dissolved in DMSO (ﬁnal concentration of <1%) and
incubated with editosome for 10min. We included
Triton X-100 (0.1% wt/vol) to prevent compounds from
aggregating and non-speciﬁc inhibition as previously
described (27). IC50 values were calculated and analyzed
using the GraphPad Prism 5 software.
RESULTS
Direct visualization of deletion RNA editing of a
hammerhead ribozyme and measuring RNA editing
eﬃciency based on HHR reporter substrate
Here, we used the pre-edited HHR which is identical to
that used in previous study (26). The pre-edited HHR has
three additional Us in its conserved catalytic region that
renders the HHR inactive. In the presence of the mito-
chondrial extract from glycerol gradient, this assay
entailed the conversion of the pre-edited HHR to an
edited HHR that depends on precise in vitro editing in
which three Us are removed as directed by the appropriate
gRNA, gA6Rbz (Figure 1A and B). It should be noted
that we have performed this assay to monitor and measure
the percentage of edited product in the conventional full
round RNA editing assay when the editosome complex
was puriﬁed from glycerol gradient fractionation. The
activity peak was observed in fraction 11 of glycerol
gradient (data not shown) and we use this fraction for
all the experiments in this article in order to have a con-
sistent comparison among diﬀerent RNA editing assays.
The mitochondrial extract concentration for this fraction
was 470mg/ml. Our results indicated that  8.8% of input
pre-edited HHR was edited by deletion of three Us. In
order to accurately report the RNA editing eﬃciency,
HHR substrate cleavage was used as a reporter (Figure
2A). Upon successful completion of full-round RNA
editing of HHR, edited functional HHR was able to
cleave its radio-labeled substrate which is 16-nt long
(Figure 2B, lane 5). We found that gA6Rbz guide RNA
had an inhibitory eﬀect on active ribozyme cleavage
activity (Figure 2D, lane 1). Figure 2C also shows that
the edited HHR cleavage activity is completely abolished
in the absence of guide RNA competitor (lane 6). This
could possibly be due to absence of enzymes with
helicase activity in this fraction. As shown previously
(36), diﬀerent methods of editosome puriﬁcation lead to
pull down of diﬀerent numbers of editosome proteins; for
example, editosome puriﬁed from sequential column chro-
matography contains an enzyme with helicase activity
which is assumed to have a role in unwinding the
mRNA from the gRNA in the editing process. This
activity could be absent from the editosome complex in
fraction 11 of glycerol gradient used throughout this
article. Hence, to resolve this issue, we added a guide
RNA competitor, which was fully complementary to
gA6Rbz in order to overcome inhibitory eﬀect of
gA6Rbz on HHR activity. We observed that 10  molar
excess of guide competitor can rescue the cleavage of
HHR substrate by active A6Rbz. On the basis of
varying concentration of active A6Rbz (positive control;
Figure 2B, lanes 6–10), we have also shown here that the
cleavage eﬃciency of the edited HHR is 33% which is
almost two times greater than the 16.8% cleavage eﬃ-
ciency reported previously (26). The in vitro editing
activity also showed a linear increase with increasing
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The RNA editing eﬃciency did not increase using higher
volume of mitochondrial extract up to 10ml (data not
shown).
FRET-based RNA editing assay
By modifying the previously reported HHR-based radio-
labeled in vitro RNA editing assay (26), we created a homo-
genous ﬂuorescent-based assay that uses a 16-nt-long
FRET substrate for real-time determination of HHR
activity after completion of full-round RNA editing.
The ﬂuorescently labeled substrate contains a ﬂuorescent
reporter (FAM) on the 50-end and a quencher (TAMRA)
on the 30-end. When the two ﬂuorophores are at close
physical proximity (10-100A ˚ ), the excited energy state of
a donor molecule is transferred non-radioactively to an
acceptor molecule, resulting in quenching of the donor
ﬂuorescence. On the other hand, when the two ﬂuoro-
phores are separated, a signal is detected upon ﬂuores-
cence dequenching. Upon RNA editing, the pre-edited
inactive ribozyme is converted to the active ribozyme
which is capable of cleaving its ﬂuorescently labeled sub-
strate and consequently a signal is detected as a result of
Edited product
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-+ -+
-- + +
Pre- A6Rbz
gA6Rbz
ME T1
Endonuclease product
Pre-A6Rbz
gA6Rbz
ES
ME
EditedSite
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B
Figure 1. Full-round HHR-based RNA editing (deletion) assay based on ATPase 6 pre-edited mRNA. (A) The pre-edited ribozyme (pre-A6Rbz) is
shown with the gA6Rbz gRNA that speciﬁes the deletion of three Us from the editing site (ES) in the presence of editosome puriﬁed from
mitochondrial extract (ME). The conserved (50-CUGA-30) of A6Rbz in the catalytic core essential for ribozyme activity is highlighted (Edited
Site) and the line indicates where the three Us are removed by editing. The 30 [
32p] pCp-label of pre-A6Rbz is indicated by an asterisk. (B)
Autoradiogram showing the edited and endonuclease cleavage products (arrows) generated only in the presence of both gA6Rbz and ME. Lane
T1 is pre-A6Rbz RNA subjected to partial digestion by RNase T1, which is used as marker. Percentage of RNA editing eﬃciency in this assay was
8.8% and it was calculated as the percentage of total input pre-A6Rbz.
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Figure 2. Cleavage activity test of HHR. (A) The structure of edited A6Rbz that can cleave the HHR substrate with the cleavage site indicated by an
arrow. The 30 [
32P] pCp-label of HHR substrate is indicated by an asterisk. The essential core nucleotides of HHR are highlighted. (B) In the
presence of mitochondrial extract, the HHR substrate cleavage can be monitored by edited pre-A6RZ. The cleavage product by edited pre-A6Rbz
was generated only in the presence of gA6Rbz and, mitochondrial extract, and gA6Rbz competitor (gA6Rbz Comp; lane 5). There was no cleavage
product detected in the absence of either mitochondrial extract (ME) or gA6Rbz gRNA (lanes 2 and 4) and there was no HHR substrate degradation
observed in the presence of ME alone (lane 3). Various concentrations of active HHR, A6Rbz, (lanes 6–10) were used to estimate the eﬃciency of
substrate cleavage by pre-A6Rbz upon RNA editing. The percentage of cleavage product was measured as the ratio of density of cleavage product
over density of the entire lane. The percent cleavage at the highest concentration of active HHR (1 pmol) was assumed to be 100% and percent
cleavage at the lower concentrations (0.1, 0.25, 0.5 and 0.75 pmol) were accordingly normalized to 23%, 57%, 88% and 95%, respectively. (C) The
in vitro RNA editing reaction followed by cleavage activity test of HHR using various amounts of ME. The input HHR substrate and cleavage
products are indicated by arrows. Lanes 1–5 contain preA6Rbz, gA6Rbz, various amounts of ME as indicated, and gA6Rbz competitor. Lane 6 is
same as lane 5 but the gA6Rbz competitor was not added to show the inhibition of HHR substrate cleavage. (D) Inhibitory eﬀect of gA6Rbz on
HHR cleavage activity (radiolabel-based assay) in the absence and presence (10 and 20 ) of gA6Rbz competitor. In the presence of increasing
molar excess of gA6Rbz competitor to gA6Rbz, the A6Rbz cleavage activity was restored.
PAGE 5 OF 13 Nucleic Acids Research, 2010,Vol.38, No. 13 e1380
0.02
0.04
0.06
0.08
0.1
0.12
Pre-A6Rbz
gA6Rbz
ME
ES
Edited A6Rbz
FRET HHR substrate
Cleavagesite
A
Pre-A6Rbz (1pmol) -+ - + +
gA6Rbz(2.5 pmol) -+ - - +
gA6Rbz Comp (25 pmol) -+ - - +
FRET HHR substrate (15 pmol) ++ + + +
ME (5µl) --+ + +
F
A
U
/
M
i
n
B
0
0.05
0.1
0.15
0.2
0.25
10 25 47 50 75 100
% A6Rbz 
% Converted pre-edited 
A6Rbz to A6Rbz
F
A
U
/
M
i
n
C
D
Figure 3. FRET-based RNA editing assay. (A) Diagram of the pre-edited ribozyme (pre-A6RZ) is shown in association with the gA6RZ gRNA that
speciﬁes the deletion of three Us from the editing site (ES). In the presence of functional mitochondrial extract (ME), the pre-A6RZ is edited to
active A6RZ that can now cleave the FRET HHR substrate with a ﬂuorescent reporter (FAM) on the 50-end and a quencher (TAMRA) on the
30-end. The cleavage site of FRET HHR substrate is indicated by an arrow. (B) FRET-based RNA editing assay. Reactions were performed in a 30ml
reaction volume under multiple turn-over conditions. Rotor-Gene 3000
TM (CORBETT research) was used as a ﬂuorescent reader. In the graph,
y-axis represents the initial velocity of reaction in terms of ﬂuorescent arbitrary unit (FAU) per minute and x-axis indicates the reaction conditions. A
high signal-to-noise ratio was measured when both gA6RZ and ME were present (compare complete reaction with other conditions). All reactions
containing gA6Rbz competitor (gA6Rbz Comp) were at 10  molar excess to gA6Rbz. The error bars represent the experimental variation (standard
deviation) from 20 repetitions and resulting in Z-value of 0.65. (C) Various concentrations of active HHR, A6Rbz, 0.1, 0.25, 0.5, 0.75 and 1 pmol
corresponding to 10%, 25%, 50%, 75% and 100% RNA editing was compared to eﬃciency of edited pre-A6Rbz FRET-based RNA editing assay.
The red column indicates that nearly 47% of inactive HHR was edited to active HHR in the presence of gA6Rbz gRNA and ME. (D) FRET-based
assay provides a linear measure of ribozyme activity. Close circles represent the measured ribozyme activity based on radiolabeled assay, whereas
open circles indicate the measured ribozyme activity based on FRET assay. The dotted line represents a perfectly theoretical linear assay.
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and the HHR substrate is shown in Figure 3A. Cleavage
of the substrate by the HHR separates the ﬂuorescent
reporter and the quencher, allowing us to monitor, in
real time, the cleavage activity of the HHR based on
a time-dependent increase of ﬂuorescence. Figure 3B
shows that upon completion of full-round RNA editing
reaction in the presence of both gA6Rbz and mitochon-
drial extract, the pre-edited inactive HHR is edited to an
active HHR which then cleaves the FRET substrate.
Z-factor is most commonly calculated to examine the
performance and quality of high throughput screening
assays. This factor is a statistical parameter which takes
into account the signal to background or signal-to-noise
ratio in such assays (35). In order to evaluate the power of
our method in discriminating between reactions in which
the RNA editing happens and reactions where no editing
occurs, we calculated the Z-factor from 20 repetitions
of each of the positive and negative reactions (Z: 0.65;
Figure 3B). This indicates a high sensitivity and speciﬁcity
for our FRET-based assay in measuring editing eﬃciency.
In order to accurately measure the edited HHR cleavage
activity, the cleavage product of ﬂuorescent substrate was
determined at varying concentrations of active HHR
(A6Rbz positive control) in the same reaction condition
(Figure 3C). Result of this experiment was used as a
standard to measure the eﬃciency of our FRET based
assay. We have measured that  47% of inactive HHR
was converted to active HHR as a result of successful
RNA editing. This suggests that the FRET-based assay
has  14% higher eﬃciency and, therefore,  1.5 times as
sensitive as the HHR radiolabeled assay (47% versus
33%). The higher sensitivity of our ﬂuorescent assay in
comparison to the radiolabeled HHR-mediated cleavage
assay can be attributed to the higher concentration of the
substrate. Unlike the radiolabeled substrate, the ﬂuores-
cent substrate can be used and detected at high concentra-
tions, allowing a more accurate measurement. More
importantly, we can measure the velocity of the reaction
using the ﬂuorescent substrate, whereas when using the
radiolabeled substrates we can only measure the end-
point concentration of the cleavage product; the former
provides a more accurate and linear estimate of the con-
centration of active ribozyme (Figure 3D).
We have also examined various factors which inﬂuence
our ﬂuorescent-based assay. First, we have shown that
gA6Rbz has inhibitory eﬀect on HHR cleavage activity;
due to the tight association of the guide RNA and A6Rbz,
the edited active HHR could not bind and cleave the
HHR substrate (Figure 4A, column 2). This problem
was overcome by adding the gA6Rbz competitor
(10 molar excess of gA6Rbz concentration; Figure 4A,
column 3). Further increasing gA6Rbz competitor con-
centration had less or similar eﬀect on cleavage activity
(Figure 4A, columns 4 and 5). Second, we have tested the
RNA editing activity of mitochondrial extract from diﬀer-
ent fractions of glycerol gradient (Figure 4B). We have
found that fractions 9–13 (Figure 4C), corresponding to
20S editosome, were able to edit inactive HHR to active
HHR, but the highest edited active HHR resulted from
fraction 11 of glycerol gradient; henceforth, we have used
this fraction for our FRET-based assay. Third, the in vitro
editing activity showed a linear increase with increasing
concentration of mitochondrial extract up to 5ml
(Figure 4D). We have also investigated the eﬀect of the
ATP concentration on the RNA editing activity. The
mitochondrial extract of T. brucei displays maximum
editing activity at ATP concentration up to 1mM. The
RNA editing eﬃciency does not plateau with higher
ATP concentrations, but rather is repressed by further
increasing levels of ATP concentration (Figure 5A). In
order to determine the potential eﬀect of ATP addition
on chelating and lowering the concentration of free
Mg
2+ required for ribozyme function, we varied the
amount of ATP in the presence of the active ribozyme
and 10mM Mg
2+ (the concentration used throughout
this study). Increasing concentration of ATP up to
6mM did not inhibit the ribozyme function, indicating
that the Mg
2+-chelating activity of ATP does not lower
the Mg
2+ concentration to a level that would inhibit
ribozyme cleavage activity (Figure 5A, dotted line). One
other likely explanation for this suppression is the inhibi-
tory eﬀect of ATP addition on RNA editing ligase activity.
This would be consistent with an earlier observation in
bacteriophage T4 RNA ligase 2 that the ATP addition
results in the accumulation of the adenylated RNA
ligase and RNA-adenylate intermediate and thus suppres-
sion of the RNA ligase activity (37). We, however, cannot
rule out the possibility of Mg
2+ chelation by higher con-
centrations of ATP and its eﬀect on the RNA editing
ligase activity. Since the optimum concentration of Mg
2+
for in vitro RNA editing has been established at 10mM
(10), we used this concentration in this study, although
increasing the Mg
2+ and ATP concentrations simultan-
eously could increase the editing eﬃciency.
dATP was used here as a possible competitive inhibitor
of ATP in the presence and absence of ATP, however no
inhibitory eﬀect was detected using this ATP analogue
(Figure 5B and C). We have also tested the eﬀect of
dimethylsulfoxide (DMSO; a commonly used solvent
for chemical compounds) on editing, measured by our
ﬂuorescence-based assay. The mitochondrial extract
was incubated with diﬀerent concentrations of DMSO
(0–10%). We found that at concentrations up to 1%
DMSO did not aﬀect the enzyme activity. However, 5%
and 10% DMSO concentrations signiﬁcantly reduced the
editosome activity (Figure 5C). In order to validate our
assay with known inhibitors of RNA editing enzymes, we
have tested two compounds against KREL1 protein (S2
and S5) reported by Amaro et al. (27). They have shown
that S5 had signiﬁcant inhibitory eﬀect on the adenylation
step of RNA editing ligase activity (IC50: 1.01±0.16mM),
whereas S2 did not perturb this step at 10mM concentra-
tion. Conﬁrming their ﬁndings, here we showed the eﬀect
of these two compounds on FRET-based full-round
deletion assay. Figure 6A shows the dose–response
curves for these two compounds, indicating IC50 values
of 2.14±0.36mM (Figure 6A, left panel) and
79.2±14.3mM (Figure 6A, right panel) for S5 and S2,
respectively. The editosome complex used in this assay
was puriﬁed by using TAP-tag (324mg/ml), based on the
tagged RNA editing ligase as previously described (31).
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KREPA2
KREPA3
KREL1
Fraction 1  3 5 7 9 11 13  15 17
F5  F7 F9 F11 F13 F15
A
B
C D
FRET HHR Substrate (15 pmol) + + + + +
A6Rbz (1 pmol) ++ + + +
gA6RbZ (2.5 pmol) -+ +++
gA6RbZ comp  -- +++
0X 10X   20X   40X
Figure 4. Cleavage of FRET HHR substrate with varying concentrations of gA6Rbz competitor and varying amounts of mitochondrial extract.
(A) Inhibitory eﬀect of gA6Rbz on HHR cleavage activity (FRET-based assay). Comparison of cleavage with active HHR (A6Rbz) using various
concentrations of gA6Rbz competitor (gA6Rbz comp). In the absence of gA6Rbz comp (0 ), the signal from cleavage of the substrate is inhibited.
In the presence of increasing molar excess of gA6Rbz comp to gA6Rbz (10 ,2 0  ,4 0  ), the A6Rbz activity was restored. (B) Western analysis of
mitochondrial extract fractionated on a 10–30% glycerol gradient. The four editosome proteins; KREPA1, KREPA2, KREPA3 and KREL1 for
which monoclonal antibodies are available are indicated. (C) Fractions from (B) were assayed for editing by the FRET-based RNA editing assay.
Maximal RNA editing activity was detected in fractions 9–13 (F9–F13) peaking in fraction 11 (F11). The y-axis represents the relative percentages
of the cleavage activity for edited HHR in each experiment. (D) Eﬀect of varying concentrations of fraction 11 from (C) on FRET-based in vitro
RNA editing assay.
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tory eﬀect of these compounds on the structure/function
of the ribozyme reporter rather than the editing reaction,
we included a control in which the eﬀect of S5 was tested
on the active A6Rbz/gA6Rbz in the absence of editosome
(Figure 6A, ‘S5 with active ribozyme’). The IC50 value
of this reaction is 79.4±23.2mM suggesting that the in-
hibition is speciﬁc to the editing reaction. Both S2 and S5
are dye-like compounds, thus, inhibition observed at
highest concentration of these drugs in our ﬂuorescent-
Figure 5. Eﬀects of ATP and DMSO on RNA editing. (A) FRET-based RNA editing assay (solid line) in the absence (0mM) and presence (0.3, 0.6,
1, 3 and 6mM) of ATP, or active ribozyme (dotted line) in the absence (0mM) and presence (1, 3 and 6mM) of ATP. The relative percentage of
editing is expressed as the percentage of the cleavage activity for edited HHR in each experiment. (B) ATP dependence. Right panel indicates the
cleavage of radiolabeled HHR substrate in the absence of ATP (lane 1), in the presence of 1mM ATP (lane 2), in the presence of both 1mM ATP
and 1mM dATP (lane 3; 1mM ATP and 1mM dATP were incubated with mitochondrial extract, lane 4; 1mM ATP and 1mM dATP were added to
the reaction buﬀer, lane 5; 1mM dATP was incubated with mitochondrial extract separately, lane 6; 1mM ATP was incubated with mitochondrial
extract separately), and in the presence of 1mM dATP and absence of 1mM ATP (lane 7), left panel was identical to right panel except FRET
substrate substituted for radiolabel substrate. (C) FRET-based RNA editing assay in the absence (0mM) and presence of varying concentrations of
DMSO (0.1–10%). The relative percentage of editing is expressed as the percentage of total cleavage in the absence of DMSO.
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by these compounds. Therefore, at higher concentrations
of the drug (after  50mM), the IC50 values measured for
S2 and active ribozyme are not reliable. We conﬁrmed the
speciﬁcity of inhibition by S5 in the FRET-based assay
using the radiolabeled full-round deletion HHR-based
assay. In this assay, higher concentrations of the drug
inhibits the editing reaction and therefore cleavage of
HHR substrate (Figure 6B, top panel), while the same
concentrations cannot inhibit the activity of active
A6Rbz in the absence of TAP-tagged puriﬁed editosome
(Figure 6B, bottom panel). IC50 value of the editing
0µM    0.1µM        1µM        10µM        50µM      100µM
Input HHR 
substrate
Cleavage 
product
0µM    0.1µM  1µM    10µM  50µM  100µM
Input HHR
substrate 
Cleavage
product
Normalized % Activity 1 1.1 1 1.2 1 1.2
IC50
A
B
Figure 6. Eﬀects of known inhibitors of RNA ligase on editosome. (A) Dose–response curves for S5 in the presence of editosome (solid line, close
circle, left panel) and in the absence of editosome in the presence of active ribozyme (dashed line, open circle, left panel), and S2 in the presence of
editosome (dashed line, close circle, right panel). IC50 and R
2-values are reported based on three independent FRET-based full-round editing assays
using editosome puriﬁed from cells expressing TbREL1-TAP. The IC50 ranges are reported with 95% conﬁdence level. The concentration of S5 that
results in 50% inhibition of maximal activity (IC50) is indicated in left panel. (B) The eﬀect of S5 on RNA editing using radiolabel-based HHR assay.
Drug concentrations in micromolars have been indicated. The dose–response curve obtained from duplicates for S5 in presence of tap-tag puriﬁed
editosome has been shown. The IC50 range is determined based on 95% conﬁdence level. The bottom panel shows the eﬀect of drug on active
A6Rbz/gA6Rbz in the absence of editosome. The percent cleavage activity (normalized percentage activity) of active ribozyme in the absence of
S5 was assumed to be 1 and percent cleavage at the higher concentrations of S5 (0.1, 1, 10, 50 and 100mM) was accordingly normalized.
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assay (Figure 6B, top panel). The diﬀerent IC50 values
observed using S5 in radiolabeled and FRET-based
assays can be explained since unlike the FRET-based
assay, the radiolabeled assay does not provide a linear
measure of ribozyme activity (Figure 3D). Thus, the
calculated IC50 value from radiolabeled-based assay may
not accurately represent the actual IC50 value.
DISCUSSION
Here, a convenient in vitro ﬂuorescent-based reporter
assay has been developed using an existing in vitro RNA
editing assay that is based on HHR activity (26). This
ﬂuorescent-based reporter assay contains a 16-nt long
FRET substrate labeled with two separate ﬂuorophores,
referred to as FAM (ﬂuorescent reporter), and TAMRA
(ﬂuorescent quencher). Theoretically, when FAM and
TAMRA are physically close to each other, the energy
shifts from FAM to TAMRA and results in de-excitation
of FAM and excitation of TAMRA, while when they get
separated from each other, FAM absorbs light and excited
state of this ﬂuorescent reporter is generated (38).
Our ﬂuorescent-based assay requires the editing of an
inactive pre-edited HHR into an active HHR which is
able to cleave its ﬂuorescence-labeled substrate; hence
much higher signal compared to background can be
detected as a result of cleavage. The editing of HHR
requires editosome puriﬁed from T. brucei. In order to
develop a highly robust and eﬃcient ﬂuorescent-based
RNA editing assay, we looked for the most active and
pure editosome preparation. Greater activity of editosome
can increase the yield of edited HHR and cleavage of its
ﬂuorescently labeled substrate and thus higher sensitivity.
The editosome preparation from whole cell mitochondrial
extract by glycerol gradient fractionation showed a high
level of activity. One important advantage of using crude
cellular fractions is that the conditions are closer to the
inhibitor to be discovered using living cells. On the other
hand, a possible drawback of less pure editosome prepar-
ation is potentially higher level of false negatives that may
inﬂuence the high-throughput screening assay. Hence,
while testing chemical compounds reported by Amaro
et al. (27), we have used a more pure editosome prepar-
ation obtained by the TAP-tag method. While they have
reported the inhibitory activity of these compounds only
on KREL1 adenylation, we further demonstrate that their
best drug-like inhibitor, S5, identiﬁed by virtual screening
against KREL1 and conﬁrmed by adenylation assay is
also able to inhibit full-round deletion RNA editing.
Virtual screening of chemical libraries against essential
protein components of editosome might lead to discovery
of drug like inhibitors but this approach is limited by the
unavailability of crystal structures of most editosome
proteins. Therefore, our assay can be a powerful tool for
identifying inhibitors against other essential components
of editosome.
The inhibitory eﬀect of gRNA on the HHR activity is
an important factor to consider. In RNA editing assays,
the gRNA concentration is always in molar excess of
pre-edited mRNA, hence during RNA editing assay
majority of the mRNAs (edited/pre-edited) form a
duplex with gRNA. This causes a problem while monitor-
ing editing in real time using ﬂuorescent based assay, since
the edited HHR is not free to cleave its substrate. We have
been able to overcome this problem by heat denaturation
of the mRNA/gRNA duplex in the presence of gRNA
competitor (in 10  molar excess) which could help to
unwind the mRNA/gRNA duplex.
A recent publication describes an RNA aptamer-based
assay to monitor the editing reaction based on electroche-
miluminescent signal. In this assay, the RNA editing of an
aptamer causes a conformational change that result in the
activation of the streptavidin-binding region of the
aptamer, leading to a measurable electrochemiluminescent
signal. In contrast, our assay is based on the enzymatic
activity of the editing substrate, i.e. the hammer-head
ribozyme. This FRET-based ribozyme assay, when
compared to the aptamer-based assay, shows a consider-
ably higher signal to background ratio (20-fold selectivity;
39). Also, our FRET-based assay is a simple ‘mix and
measure’ homogeneous assay that is much simpler and
less time-consuming compared to the aptamer-based
assay, particularly because it involves no washing steps.
Most importantly, the real-time monitoring of cleavage
activity of HHR yields a series of time points with any
desired resolution, whereas the aptamer-based assay relies
on endpoint signal. This confers a higher accuracy in
measuring the amount of edited product (active HHR).
Taken together, we have successfully adapted our
ribozyme-based assay for use in high-throughput molecu-
lar screening against the whole editosome. A Z-value of
0.65 for full-round deletion RNA editing based on A6Rbz
indicates that this assay is suitable for high-throughput
screening of chemical compounds against editing machin-
ery. It can be estimated that preparation of mitochondrial
extract from 40l of T. brucei culture using 2ml of pooled
fractions (9–12) of glycerol gradient can yield enough ma-
terials for screening 40000 compounds in search of inhibi-
tors of editing reaction. We calculated the Z-value of 0.6
(data not shown) using this pooled fraction which is
slightly lower than the Z-value calculated for the
fraction with highest editing activity but still in a desirable
range for high-throughput screening. We have also shown
that the ﬂuorescent based RNA editing assay demon-
strates a greater sensitivity; up to 5-fold more than con-
ventional radiolabel based assay. Furthermore, other
major advantages of this method are that the use of radio-
active material can be avoided and time-consuming gel
electrophoresis can be circumvented. We are currently de-
signing a truncated HHR that can be adapted for
pre-cleaved RNA editing assays which are particularly
useful in examining the U insertion, U deletion, and
ligation catalytic steps of RNA editing. FRET based
pre-cleaved RNA editing assays using truncated version
of HHR will also serve as a secondary screen to validate
the speciﬁcity of the inhibitory compounds.
Furthermore, RNA editing is not limited to the inser-
tion and deletion of uridines in mitochondrial encoded
RNAs of kinetoplastid, as other types of RNA editing
have been described which result in non-encoded
PAGE 11 OF 13 Nucleic Acids Research, 2010,Vol.38, No. 13 e138adenosines, guanosines, cytidines and inosines by substi-
tution type of RNA editing. The latter type of RNA
editing has been observed in chloroplast-encoded RNAs
of plants (40) as well as nucleus-encoded RNAs of
mammals (41). Our ﬂuorescent-based HHR assay can
also be adapted to monitor such processes in order to
elucidate the mechanisms involved in this type of RNA
editing process using cell-free extracts.
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